恶性间皮瘤：免疫检查点抑制剂和间皮素靶向治疗的进展。
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
机构信息
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
出版信息
Cancer. 2021 Apr 1;127(7):1010-1020. doi: 10.1002/cncr.33433. Epub 2021 Feb 23.
Abstract
Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.
摘要
恶性间皮瘤是一种侵袭性癌症，预后不良，治疗选择有限。多年来，美国食品和药物管理局唯一批准的不可切除间皮瘤的一线治疗方法是培美曲塞加顺铂。然而，最近批准纳武单抗加伊匹单抗作为胸膜间皮瘤患者的一线治疗方法，标志着这种疾病治疗的一个重要里程碑。在这篇综述中，作者描述了治疗晚期不可切除间皮瘤患者的治疗策略的最新进展，重点介绍了免疫疗法和间皮素靶向疗法在恶性间皮瘤治疗中的应用。
相似文献
1
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.恶性间皮瘤：免疫检查点抑制剂和间皮素靶向治疗的进展。
Cancer. 2021 Apr 1;127(7):1010-1020. doi: 10.1002/cncr.33433. Epub 2021 Feb 23.
2
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.CheckMate 743：恶性胸膜间皮瘤的一线希望
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
3
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.免疫检查点抑制治疗不可切除的恶性胸膜间皮瘤。
Drugs. 2021 Jun;81(9):971-984. doi: 10.1007/s40265-021-01506-0. Epub 2021 Jun 9.
4
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.将 PD-L1 抑制剂阿特珠单抗与 WT1/DC 疫苗联合用于上皮样恶性胸膜间皮瘤患者的标准一线治疗：Immuno-MESODEC 研究方案。
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
5
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.纳武利尤单抗和伊匹单抗治疗恶性胸膜间皮瘤的疗效与效应记忆细胞毒性 T 细胞亚群有关：来自两项临床试验的转化证据。
EBioMedicine. 2020 Dec;62:103040. doi: 10.1016/j.ebiom.2020.103040. Epub 2020 Nov 7.
6
Nivolumab plus ipilimumab in malignant pleural mesothelioma.尼伏单抗联合伊匹单抗治疗恶性胸膜间皮瘤。
Expert Rev Anticancer Ther. 2022 Aug;22(8):815-822. doi: 10.1080/14737140.2022.2102482. Epub 2022 Jul 25.
7
[New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].[新的上市授权申请：一线纳武利尤单抗联合伊匹木单抗用于不可切除的恶性胸膜间皮瘤]
Bull Cancer. 2022 Jan;109(1):4-6. doi: 10.1016/j.bulcan.2021.07.010. Epub 2021 Oct 13.
8
Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.突破恶性间皮瘤传统间皮素靶向嵌合抗原受体T细胞疗法的治疗困境：展望未来
Pharmacol Res. 2024 Jun;204:107220. doi: 10.1016/j.phrs.2024.107220. Epub 2024 May 18.
9
Nivolumab for the treatment of unresectable pleural mesothelioma.尼伏鲁单抗治疗不可切除性胸膜间皮瘤。
Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16.
10
True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.免疫检查点抑制剂在日本恶性胸膜间皮瘤治疗中的真正获益
Anticancer Res. 2024 Oct;44(10):4135-4145. doi: 10.21873/anticanres.17244.
引用本文的文献
1
Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports.一线使用卡铂、培美曲塞和贝伐单抗治疗腹膜间皮瘤取得成功：两例病例报告
Case Rep Oncol. 2025 Jan 30;18(1):278-285. doi: 10.1159/000543889. eCollection 2025 Jan-Dec.
2
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy.载有瑞喹莫德的热敏脂质纳米颗粒促进肿瘤相关巨噬细胞极化以增强膀胱癌免疫治疗
ACS Nano. 2025 Jun 3;19(21):19599-19621. doi: 10.1021/acsnano.4c17444. Epub 2025 May 17.
3
Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma.双向孟德尔随机化研究及对肠道微生物群与恶性间皮瘤因果关系的潜在机制见解
Medicine (Baltimore). 2025 Apr 25;104(17):e42245. doi: 10.1097/MD.0000000000042245.
4
Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.辣椒素对间皮瘤细胞具有抗肿瘤活性。
Nutrients. 2024 Nov 1;16(21):3758. doi: 10.3390/nu16213758.
5
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.弥漫性胸膜间皮瘤患者靶向治疗方法的过去、现在与未来
J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.140. Epub 2023 May 30.
6
Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.全球 204 个国家和地区归因于职业性石棉暴露的间皮瘤全球负担：1990-2019 年。
J Cancer Res Clin Oncol. 2024 May 28;150(5):282. doi: 10.1007/s00432-024-05802-6.
7
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.双特异性抗体与免疫检查点阻断联合疗法治疗癌症的疗效和安全性：真实世界比较。
Mol Cancer. 2024 Apr 16;23(1):77. doi: 10.1186/s12943-024-01956-6.
8
Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies.利用纳米抗体功能化的磁荧光纳米组装体特异性靶向表达间皮素的恶性细胞。
Int J Nanomedicine. 2024 Jan 20;19:633-650. doi: 10.2147/IJN.S435787. eCollection 2024.
9
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.立体定向体部放疗治疗恶性胸膜间皮瘤的临床疗效。
Radiother Oncol. 2024 Feb;191:110057. doi: 10.1016/j.radonc.2023.110057. Epub 2023 Dec 15.
10
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.一名卵巢恶性间皮瘤患者中新型STRN-ALK与NBEA-ALK双融合的共存：病例报告与文献复习
Front Oncol. 2023 Apr 21;13:1156329. doi: 10.3389/fonc.2023.1156329. eCollection 2023.
本文引用的文献
1
FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.FDA 批准尼伏鲁单抗联合伊匹单抗用于未经治疗的不可切除恶性胸膜间皮瘤。
Oncology (Williston Park). 2020 Nov 12;34(11):502-503. doi: 10.46883/ONC.2020.3411.0502.
2
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.一项比较派姆单抗与单药化疗治疗晚期预处理恶性胸膜间皮瘤的多中心随机 III 期试验：欧洲胸部肿瘤平台（ETOP 9-15）PROMISE-meso 试验。
Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22.
3
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.LMB-100 免疫毒素治疗表达间皮素的间皮瘤和其他实体瘤患者的 1 期临床研究。
Cancer. 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145. Epub 2020 Sep 1.
4
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.间皮素靶向免疫毒素LMB-100与抗PD-1抗体在间皮瘤患者及小鼠肿瘤模型中的疗效增强
Sci Transl Med. 2020 Jul 1;12(550). doi: 10.1126/scitranslmed.aaz7252.
5
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?恶性胸膜间皮瘤的新兴治疗方法：我们将何去何从？
Front Oncol. 2020 Mar 12;10:343. doi: 10.3389/fonc.2020.00343. eCollection 2020.
6
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.人用首仿，多中心，I 期剂量递增和扩展研究抗间皮素抗体药物偶联物 Anetumab Ravtansine 在晚期或转移性实体瘤中的应用。
J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26.
7
Peritoneal mesothelioma.腹膜间皮瘤
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S120-S132. doi: 10.21037/tlcr.2019.12.15.
8
Nivolumab for the treatment of unresectable pleural mesothelioma.尼伏鲁单抗治疗不可切除性胸膜间皮瘤。
Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16.
9
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.嵌合抗原受体修饰的慢病毒转导 T 细胞识别间皮素治疗晚期实体瘤的 I 期临床研究。
Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.
10
Clinical Efficacy and Safety of Nivolumab: Results of a ulticenter, Opn-label, Single-am, Japanese Phase II study in Malgnant Pleural Mesohelioma (MERIT).尼伏鲁单抗的临床疗效和安全性：一项多中心、开放标签、单臂、日本恶性胸膜间皮瘤（MERIT）Ⅱ期研究结果。
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.
Zotero 插件